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Introduction
Autoimmune hemolytic anemia (AIHA) is
an immunohematologic disorder in which
antibodies are produced against the body's red
blood cells (RBC). It is one of the oldest rec-
ognized immune-mediated diseases of both
humans and dogs, and has also been recog-
nized in the cat, horse, mouse, pig and guinea
pig. 1,2 There has been a significant increase in
the number of dogs recognized to have
AIHA. 3 Since 1979, hematologic reference
laboratories have noted a two to three fold
increase in the number of cases of canine im-
mune mediated diseases. 4 Whether this is due
to a true increase in the prevelence of the dis-
ease or an increased awareness among veteri-
narians is questioned. However, research has
shown that the current increase reflects a true
increase in the frequency of the disease. 3
AIHA occurs more often in females, spayed
or intact, by a ratio of 3: 1 and has been ob-
served in dogs six weeks to fifteen years of
age, with an average age of onset of four to
five years. 1 ,3,4 Genetic predisposition applies
to Inany ilnmunologic diseases and AIH.A is
no exception. Breeds apparently predisposed
to AIHA include American Cocker Spaniels,
Miniature Dachsaunds, Minature and Toy
Poodles, Scottish Trerriers, Irish Setters,
Vizlas, German Shepards, Shetland Sheep-
dogs and Old English Sheepdogs. 3 ,4
Etiology and Pathogenesis
Hemolytic anemia is defined as a decreased
number of circulating RBCs as a result of a
shortened RBG life span. Hemolytic anemia
may be divided into three types; intravascu-
lar, extravascular, or fragmentation. Hemoly-
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sis may be the result of intracorpuscular ab-
normalities of structure or function,
abnormalities of the RBC membrane or ex-
tracorpuscular abnormalities of the plasma
constituents and vascular elements. to AIHA is
characterized by antibody-mediated destruc-
tion of RBGs. Primary AIHA is antibody
directed against unaltered RBC s. This is a
true autoimmune disease with antibody pro-
duced against "self' antigens. For reasons un-
known, the mechanism of immunological tol-
erance of the host's ability to distinguish
between "self' and "non-self' has failed. 6 Sec-
ondary AIHA is an immune-mediated disease
triggered by RBGs antigenically altered by
foreign antigens such as microorganisms or
by drugs producing a hapten-RBC complex.
The normal immune system no longer recog-
nizes these cells as "self' and produces anti-
body against these new antigens. The anti-
gen-antibody reaction which occurs at the
RBC surface results in the structural and
functional changes prerequisite for hemolysis
and subsequent anemia.
Secondary AIHA or immune-mediated he-
molytic anemia occurs rnore commonly than
does primary AlBA. Microorganisms, drugs,
stress and under-lying disease are capable of
inducing the immune system to produce anti-
bodies directed against "self' antigens. Micro-
organisms, especially viruses that infect
lymphoid tissues are capable of interfering
with immunologi~al control. With respect to
AIHA in human$, Mycoplasmal pneumonia
and several viruses such as infectious
mononucleosis have been incriminated3 . Cor-
onavirus, parvovirus and distemper virus
have been suggested as causes of immune-me-
diated hemolytic anemia in dogs. 4 Exposure
to modified live virus vaccines has been spec-
ulated as a trigger to immune-mediated dis-
ease. 4 Dogs vaccinated with modified live
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canine parvovirus or cats vaccinated with fe-
line panleukopenia vaccines have shown clini-
cal signs consistent with AIHA. The possibil-
ity exists that frequent exposure to
monovalent or multivalent modified live vac-
cines sensitizes a susceptible host to viral anti-
gen and increases the risk of developing im-
mune-mediated reactions. 3 ,4
Drug-induced immune hemolysis does oc-
cur in humans and animals. 3 Drug adminis-
tration causes from 16-18 % of acquired im-
mune-mediated hemolytic anemias in
humans. 13 Three mechanisms have been pro-
posed to account for RBG antigenic modifica-
tion; a hapten mechanism, an immune com-
plex formation and true autoantibody
induction. 14 In the hapten mechanism the
drug combines with the RBC ll1embrane and
antibody develops against the drug or hapten.
With a second exposure to the drug this anti-
body destroys the drug-coated RBG. Large
doses of penicillin or cephalothin may cause
this reaction. Drugs such as phenacetin or
phenylthiazine can combine with antibody to
form an immune complex. This complex may
then be adsorbed to the RBC membrane.
This process activates complement which
leads to lysis of the RBC. Since RBCs are
only secondarily involved in this process, it
has been termed the "innocent bystander"
mechanism. 13 Alpha-methyldopa (Aldomet),
an anti-hypertensive agent, has produced
AIHA in 10-36% of humans administered
the drug. 14 It is speculated that alpha-methyl-
dopa alters the RBG membrane in such a way
that the immune system no longer recognizes
the RBC as "self:'13
Clinical episodes of AIHA are often precip-
itated by stress and underlying disease. 14
Pregnancy, infection, trauma or surgery may
be predisposing factors. 1 Lymphocytic leuke-
mia, lymphphosarcoma and reticulum cell
sarcoma and other autoimmune disorders
such as systemic lupus erythematosus,
rheumatoid arthritis and immune-mediated
thrombocytopenia are commonly associated
with AIHA. 3
As noted above, RBG destruction is- a con-
sequence of intravascular lysis, extravascular
erythrophagocytosis or RBG fragmentation.
In AIHA, RBGs become coated with anti-
body, complement or both. 11 Intravascular
\hemolysis is generally associated with comple-
\ment fixation leading to cell lysis. With ex-
travascular erythrophagocytosis, opsonized
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RBCs are phagocytized and destroyed by
macrophages of the spleen, liver, and bone
marrow.
In intravascular hemolysis, RBGs are op-
sonized with immunoglobulin (IgG), IgM or
both. Both immunoglobulins are capable of
fixing or activating the complement cascade.
Antibodies capable of complement (C') fix-
ation have the greatest potential to cause he-
molysis. ll Intravascular hemolysis is more
commonly associated with IgM. A single mol-
ecule of IgM, due to its large molecular size,
can fix a single molecule of complement and
activate the complement cascade. In contrast,
doublets or two molecules side by side are re-
quired for complement fixation with IgG. 10,12
Extravascular hemolysis is more common
than intravascular hemolysis in immune-me-
diated reactions. 10 IgG-mediated erythropha-
gocytoisis occurs more commonly than with
IgM. l1 Macrophages in the spleen and liver
possess receptors for IgG and C3. RBGs
opsonized with IgG or C3 or both react with
these macrophages. This leads to partial or
complete phagocytosis of the RBC, and oc-
curs primarily in the spleen. With partial
phagocytosis only a portion of the RBC mem-
brane is phagocytized. This leads to a change
in the cell shape from biconcave to sphero-
cytic. Spherocytes are small, dense, uniform
sized RBGs that have lost the central pallor of
a normally biconcave shaped RBG. Spherocy-
tes are rigid cells unable to deform as normal
RBCs must in the circulation. Their intravas-
cular life span is reduced since they cannot
sustain the trauma of the microcirculation,
particularly in the spleen where they are re-
moved. 11
AIHA syndromes are a heterogeneous
group of disorders or syndromes that vary
with their severity of clinical manifestations
and in the properties of antibody involved. 9 A
classification system has been established to
describe the involved antibody type and to de-
termine a prognosis for dogs with AIHA. 9 ,15
Class I, or in-saline acting autoagglutinins,
includes those antibodies that cause intravas-
cular hemagglutination. Agglutination is ob-
served immediately after withdrawl of blood
and upon placing the blood into a glass tube
or vial. Agglutination is also seen when blood
is placed on a glass slide . Non-C I fixing IgG
molecules bind to the RBC membrane. These
IgG-RBC complexes then bind together at
their Fc portions causing agglutination. This
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agglutination should be differentiated from
normal rouleau formation by mixing the
blood with an equal portion of saline.
Rouleau formation will disperse, auto-ag-
glutination will not. The finding of in-saline
auto-agglutinins is diagnostic for AIHA.
Prognosis for a dog with this type of AIHA is
generally poor.
Class II, or intravascular hemolysins, are
antibodies (usually IgM) that fix C / and re-
sult in massive intravascular hemolysis. There
is massive destruction of RBC s and hemoglo-
binuria and hemoglobinemia occur. Prognosis
for this type of AIHA is' also generally poor.
Class III, or incomplete antibody type, is
the most common form of AIHA in the dog.
RBCs are opsonized usually with IgG of in-
, sufficient quantity or avidity to cause direct
intravascular hemolysis. RBC destruction oc-
curs primarily through the reticuloendothelial
system of the spleen. The onset of clinical
signs is gradual and this form of AIHA usu-
ally runs a chronic course.
Class IV, or cold hemagglutinins, are ag-
glutinating antibodies, usually C / fixing IgM
that are most active at temperatures below
37 °C. This disease is seen with cold weather.
Ischemia involving the extremities is due to
intravascular agglutination in small blood ves-
sels. Cold hemagglutinins can be detected by
visual clumping of blood at colder tempera-
tures, and resuspension at 37°C.
Class V, or cold acting nonagglutinating
AIHA involves antibodies which do not cause
agglutination but lead to increased RBC de-
struction, particularly in cold weather. Icterus
and hemoglobinuria are common. This dis-
ease is rare ann is usually neither acute nor
severe.
Clinical Presentation
Common presenting signs of dogs with
AIHA include decreased activity, depression,
weakness, anorexia and in acute cases the
sudden collapse of a previously healthy ani-
mal. 5,6 Hemoglobinuria may be a presenting
con1plaint as may tachypnea and respiratory
distress. Physical examination of dogs with
AIHA will generally reveal extremely pale
n1UCOUS membranes. Icterus may be an
accompanying clinical sign. Lymphadeno-
pathy, fever, emesis, and hepatosplenomegaly
are frequently seen.
These clinical presenting signs are vague
and in no manner diagnostic for AIHA. Ob-
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served clinical signs depend on the cause of
RBC destruction and the rate at which it oc-
curs; the ability of the bone marrow to in-
crease RBC production; the ability of the liver
to extract bilirubin from RBC breakdown; the
amount of haptoglobin available to bind with
free hemoglobin preventing escape through
the kidneys; and presence of concurrent dis-
ease. 6 Supporting laboratory data is thus nec-
essary to confirm a diagnosis of AIRA. A
complete hemogram of a patient with AIHA
will reveal values consistent with a hemolytic
anemia. Pack cell volumes (PCV) will de-
crease. PCVs below 20% with many between
10-15 % qre common and values below 8 %
have been'.' found. 1,7 Blood smears of AIHA
patients will often reveal numerous spherocy-
tes, and anisocytosis and polychromasia may
also be present. Autoagglutination of sphero-
cytes may be observed in a blood smear or
visible grossly in a glass vial. 1 Evidence of a
bone marrow response to the anemia is
present in most peripheral blood smears. Re-
ticulocytes or polychromatic RBCs will in-
crease in number representing a regenerative
response by the bone marrow. Reticulocyte
counts of over 20 % have been encountered. 4
Total white blood cell counts are mildly to
severely elevated with accompanied regenera-
tive left shifts. 5, 7,9 This leukemoid response
accompanies the highly regenerative bone
marrow response at the pleuripotent stem cell,
and m·ay be misinterpreted as a sign of sepsis.
The mean corpuscular volume (MCV) or the
average RBC volume is increased. This is ac-
companied by a decrease in the mean corpus-
cular hemoglobin concentration (MCRC) or
the percentage concentration of hemoglobin
in the RBC. Urinalysis may reveal hemoglo-
binuria and hemoglobin crystals. 8
Diagnosis
The diagnosis of AIHA is based upon his-
tory, clinical presentation, clinical pathology
and a positive direct Coombs' test. Smears of
patient's blood may reveal several parameters
necessary for the diagnosis of AIHA. Autoag-
glutination of RBCs may be observed which
needs to be distinguished from normal
rouleau formation. Spherocytes may be ob-
served. Since the anemia generally associated
with AIHA is regenerative, high reticulocyte
counts are common but in some instances re-
ticulocytes may be rare or absent. Anemia
characterized by lack of reticulocytes or by an
Iowa State University Veterinarian
erythroid hypoplasia suggests the autoim-
mune process is not only directed against cir-
culating RBCs but against bone marrow
erythrocytes precursors as well. This type of
anemia has been termed pure red cell aplasia
and has been reported in both humans and
animals. 2 Marked polychromasia and aniso-
cytosis will be present in a peripheral blood
smear of a dog with AIHA due to the pres-
ence of normal circulating RBCs spherocytes
and reticl.llocytes.
The most specific aid in the diagnosis of
AIHA is the direct antiglobulin test also
known as the Coombs test. By using the
Coornbs test it is possible to determine which
antibody type (IgG, IgM) or complement
component is fixed to the RBC emmbrane. 16
One study recognized four principal types
of immune mediated reactions; IgG alone
(11.2% of reactions), IgG+C! (30.6%), C'
alone (55%), and IgM+C' (1.5%).17 This
information is valuable to know so that testing
of AIHA will include checking for the pres-
ence of the two n10st common types of RBC
antibodies by using either a broad spectrum
antiglobulin serum or preferably individual
anti-IgG and anticompliment sera. 6
An enzyme-linked immunosorbant assay
(ELISA) has been developed to detect antibo-
dies bound to canine RBCs. 18 Elisa testing
may be able to detect lower antibody concen-
trations due to the greater sensitivity of its
indicator system since the measurement of
reaction is done by spectrophotometry rather
than by visual interpretation as with the
Coombs' test. It is also speculated that the
ELISA results may correlate more closely to
the severity of the clinical disease. Studies in-
dicate the potential use of a two part screening
procedure for AIHA. The first part would be
to perform the routine Coornbs test. A
Coombs positive would also test ELISA posi-
tive, thus positive for AIHA. If the Coombs
was negative, the ELISA would be performed
to detect Coombs false-negatives occurring
because the antibody concentration was too
high or below the level of sensitivity of the
Coombs test.
Treatment
The aims in treatment of AIHA are to
manage the acute anemic crisis, inhibit the
sequestration and phagocytosis of RBCs in
the reticuloendothelial system, treat specifi-
cally any underlying disease and lower the
UJI. 47) No. 1
production ofanti-RBC antibody in lymphoid
tissue. 9 The traditional treatn1ent of choice
has been the use of corticosteroids. The mech-
anism of corticosteroid activity in alleviating
the characteristics of AIHA are unknown. It
has been postulated that corticosteroids de-
crease the production of anti-RBC antibody. 12
Corticosteroids may decrease antigen anti-
body interactions thus preventing RBC sen-
sitization. 7 Another possibility of corticoster-
oid activity is that they may inhibit clearance
of antibody coated RBCs by fixed macro-
phages in the spleen and liver. Corticosteroids
may directly inhibit macrophage function by
paralyzing Fc recepters on macrophages or by
reducing the number of Ig and C' receptors
on these macrophages. 12 Whatever mecha-
nism is involved, the effect of corticosteroid
therapy is quite rapid, occurring 24-48 hours
after onset of therapy. 19 Dexamethasone is re-
garded as the corticosteroid of choice by
some; 19 prednisone and prednisolone are the
choice of others. 5.7.9 Dosage for either regime
is 2-4mg/kg/day for 5-7 days. Corticosteroid
therapy is continued on a dose reduction
schedule over a three month period. The
packed cell volun1e should be monitored
weekly during this initial therapy. Once the
packed cell volume reaches 20 %, alternate-
day therapy with prednisolone and predni-
sone may be initiated. When the packed cell
volume reaches normal values and has stabi-
lized, and the patient appears clinically nor-
mal, corticosteroid therapy should gradually
be ceased. A sudden or complete stop of corti-
costeroid therapy n1ay cause a relapse of the
anemia. An episode of AIHA may predispose
a patient to bacterial infection therefore anti-
biotics should be co-administered with the
corticosteroid therapy.
Immunosupressive agents and antimetabo-
lites are also used to treat AIHA. 6 ,19 This
treatment is resery~d for animals resistant or
nonresponsive to corticosteroids. Immunosu-
pressive agents (vincristine, cyclophos-
phamide) and antimetabolites (azathioprine,
mercaptopurine) improve RBC survival by
interfering with antibody production against
the RBC. 9 ,12 Toxic side effect of immunosup-
pressive agents and antimetabolic therapy are
possible, however when used in combination
with corticosteroids it is an effective method of
treatment in difficult cases. 19 Immunosupres-
sive and antimetabolic therapy has also been
effective in patients showing auto-agglutina-
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tion or intravascular hemolysis the types of
AIHA with poorest prognosis. 9
Splenectomy, resulting in decreased clear-
ance of antibody coated RBCs, has been used
to control AIHA. 6 Splenectomy may be nec-
essary in corticosteroid refractory animals, in
patients with frequent relapse or when corti-
costerods are required in large doses. Cur-
rently, splenectomy for the initial treatment of
A'IHA is not given much conisderation. 6 •19
Splenectomized dogs are more susceptible to
severe infectious disease. Only when all other
treatments have failed should splenectomy be
considered.
Blood transfusions should be avoided in the
treatment of AIHA with the exception of ex-
treme life-threatening situations. Blood trans-
fusions may precipitate or accelerate the he-
molytic crisis, enhance antibody production
or suppress the normal bone marrow response
to the anemia. Good supportive care, the
elimination of stress and oxygen supplemen-
tation if necessary will often sustain patients
during a hemolytic crisis.
Summary
AIHA is an immunologic disorder charac-
terized by antibody-mediated destruction of
the patient's RBCs. There are several recog-
nized types of AIHA and they differ in their
characteristics of auto-antibody involved as
well as their clinical presentation and progno-
sis. Diagnosis is based upon history and clini-
cal signs, hematology and a positive Coombs
test. Prompt treatment with corticosteroids
usually will halt the antibody-mediated de-
struction of RBCs. More aggressive treat-
ment with cytotoxic drugs and splenectomy
may be necessary in cases with poor progno-
SIS.
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